Longeveron Announces Positive Results for Aging-Related Frailty Therapy

martes, 2 de diciembre de 2025, 9:21 am ET1 min de lectura
LGVN--

Longeveron has developed a patent for methods of administering isolated allogeneic mesenchymal stem cells (MSCs) to treat aging-related frailty and non-ischemic dilated cardiomyopathy. The company's therapy, Laromestrocel, has shown positive results in two clinical trials for aging-related frailty, which affects older individuals and impairs healthspan. No approved treatments currently exist for this condition.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios